Unclassified antiphospholipid antibodies may improve the accuracy of the diagnosis of antiphospholipid antibody syndrome
10.3760/cma.j.cn114452-20200817-00665
- VernacularTitle:未纳入分类标准的抗磷脂抗体或可提高抗磷脂综合征诊断准确率
- Author:
Xiaodan ZHAI
;
Shuo YANG
;
Liyan CUI
- From:
Chinese Journal of Laboratory Medicine
2021;44(4):347-351
- CountryChina
- Language:Chinese
-
Abstract:
Antiphospholipid syndrome(APS) is a autoimmune system disorder caused by thrombosis and is usually accompanied with persistent positive. Antiphospholipid antibodies profiles(aPLs) is the key to diagnosing APS. The most frequently detectable aPLs in current clinical applications are anticardiolipin antibodies (aCL), anti-β2 glycoprotein Ⅰantibodies (anti-β2 GPI), and lupus anticoagulant (LA).However, it is found that the current laboratory diagnostic standard for APS based on these three aPL have many defects. The standard can′t meet the clinical needs. In this article, the research and development of antiphospholipid antibody in recent years are summarized, and the clinical value of non-classified standard antibodies such as IgA antibody isotype and anti-domain 1 β2-glycoprotein I antibody are reviewed.